Yilong Zhang, Ph.D.
Affiliations: | 2002 | Ohio State University, Columbus, Columbus, OH |
Area:
Pharmacy, Pharmacology, Oncology, Molecular BiologyGoogle:
"Yilong Zhang"Parents
Sign in to add mentorJessie L. Au | grad student | 2002 | Ohio State | |
(Induction of FGF as a mechanism of acquired anticancer drug resistance.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Doi T, Yamaguchi K, Komatsu Y, et al. (2017) A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Japanese Journal of Clinical Oncology. 1-8 |
Glisson B, Besse B, Dols MC, et al. (2017) A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer |
Villalona-Calero MA, Otterson GA, Wientjes MG, et al. (2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1903-9 |
Zhang Y, Song S, Yang F, et al. (2001) Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. The Journal of Pharmacology and Experimental Therapeutics. 299: 426-33 |